MDR1 gene expression in endometrial carcinoma

International Journal of Gynecological Cancer

Volumn 13, Issue 5, 2003, Pages 673-677

  Terek, Mustafa Cosan ^a   Zekioglu, O ^a   Sendag, F ^a   Akercan, F ^a   Ozsaran, A ^a   Erhan, Y ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Endometrial cancer; Immunohistochemistry; Multidrug resistance; P glycoprotein

Indexed keywords

DYE; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MDR 1 GENE; MUCINOUS CARCINOMA; MULTIDRUG RESISTANCE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, HORMONE-DEPENDENT; P-GLYCOPROTEIN; TUMOR MARKERS, BIOLOGICAL;

EID: 1242336871     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13324.x     Document Type: Article

References (16)

1. Van der Zee AGJ, Hollema HH, de Brujin HW. Cell biological markers of drug resistance in ovarian carcinoma. Gynecol Oncol 1995;58:165-78.
2. Lehnert M. Clinical multidrug resistance in cancer: a multifactorial problem. Eur J Cancer 1996;32:912-9.
3. Germann UA. Molecular analysis of the multidrug transporter, P-glycoprotein. Cytotechnology 1998;27:31-60. 4.
4. Cianfriglia M, Cenciarelli C, Barca S, Tombesi M, Flego M, Dupuis ML. Monoclonal antibodies as a tool for structure-function studies of the MDR1-P-glycoprotein. Curr Protein Pept SC 2002;3:513-30.
5. Germann UA. Detection of recombinant P-glycoprotein in multidrug resistant cultured cells. Mol Biotechnol 2000;14:131-45.
6. Baekelandt MM, Holm R, Nesland JM, Trope CG, Kristensen GB. P-glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer. Anticancer Res 2000;20:1061-7.
7. Hirose M. Biology and modulation of multidrug resistance (MDR) in hematological malignancies. Int J Hematol 2002;76:206-11.
8. Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, Mychalczak BR. The significance of the amount of myometrial invasion in patients with stage IB endometrial carcinoma. Cancer 2002;15:316-21.
9. Kanamori Y, Kigawa J, Itamochi H, Sultana H, Suzuki M, Ohwada M. PTEN expression is associated with prognosis for patients with advanced endometrial carcinoma undergoing postoperative chemotherapy Int. J Cancer 2002;20:686-9.
10. Ozsaran AA, Turker S, Dikmen Y, Erhan Y, Itil I, Terek C, Ozdemir N. P53 staining as a prognostic indicator in endometrial carcinoma. Eur J Gynaecol Oncol 1999;20:156-9.
11. Chan H, Thorner P, Haddad G. Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J Clin Oncol 1990;8:689-93.
12. Arceci RJ. Clinical significance of P-glycoprotein in multidrug resistance malignancies. Blood 1993;9:2215-20.
13. Chan HS, Haddad G, Thorner PS. P-glycoprotein expression as a predictor of therapy for neuroblastoma. N Engl J Med 1991;325:1608-10.
14. Dikmen Y, Terek MC, Sendag F. Expression of chemoresistance marker P-glycoprotein in women with epithelial ovarian carcinoma. Artemis 2002;3:63-9.
15. Kuo DYS, Mallick S, Shen HJ et al. Analysis of MDR1 expression in normal and malignant endometrium by revers transcription-polymerase chain reaction and immunohistochemistry. Clin Cancer Res 1996;2:1981-92.
16. Esteller M, Martinez Palones JM, Garcia A, Xercavins J, Reventos J. High rate of MDR-1 and heterogenous pattern of MRP expression without gene amplification in endometrial cancer. Int J Cancer 1995;63:798-803.